(Q45155852)

10 December 2017

title

Comparative effects on intestinal absorption in situ by P-glycoprotein-modifying HIV protease inhibitors (English)

1 reference

10 December 2017

Martin Richter

1

1 reference

10 December 2017

Nóra Gyémánt

series ordinal

2

1 reference

10 December 2017

Joséf Molnár

series ordinal

3

1 reference

10 December 2017

Andreas Hilgeroth

series ordinal

4

1 reference

10 December 2017

publication date

1 October 2004

1 reference

10 December 2017

published in

Pharmaceutical Research

1 reference

10 December 2017

volume

21

1 reference

10 December 2017

issue

10

1 reference

10 December 2017

page(s)

1862-1866

1 reference

P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound.

10 December 2017

cites work

1 reference

12 December 2020

Current knowledge and future prospects for the use of HIV protease inhibitors

1 reference

12 December 2020

Mechanisms and timing of mother-to-child transmission of HIV-1

1 reference

12 December 2020

Interactions of HIV protease inhibitors with ATP-dependent drug export proteins

1 reference

12 December 2020

Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein

1 reference

12 December 2020

Formulation of HIV protease inhibitors. Pharmaceutical technology and biopharmaceutic aspects of HIV protease inhibitors

1 reference

12 December 2020

Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds

1 reference

12 December 2020

HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833.

1 reference

12 December 2020

Dimeric 4-aryl-1,4-dihydropyridines as novel HIV-1 protease inhibitors--affinities to intestinal P-glycoprotein

1 reference

12 December 2020

Comparison of furosemide and vinblastine secretion from cell lines overexpressing multidrug resistance protein (P-glycoprotein) and multidrug resistance-associated proteins (MRP1 and MRP2).

1 reference

12 December 2020

Dimeric 4-Aryl-1,4-dihydropyridines: development of a third class of nonpeptidic HIV-1 protease inhibitors

1 reference

12 December 2020

P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir

1 reference

12 December 2020

Effect of dexamethasone on the intestinal first-pass metabolism of indinavir in rats: evidence of cytochrome P-450 3A [correction of P-450 A] and p-glycoprotein induction

1 reference

12 December 2020

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors

1 reference

12 December 2020

Pretreatment with potent P-glycoprotein ligands may increase intestinal secretion in rats

1 reference

12 December 2020

Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein

1 reference

12 December 2020

Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.

1 reference

12 December 2020

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

1 reference

12 December 2020

10.1023/B:PHAM.0000045240.81664.BE

Identifiers

DOI

1 reference

10 December 2017

1 reference